ClinicalTrials.gg
TerminatedNCT01291134Updated Mar 3, 2022

PureGen: Radiographic Analysis of Fusion for ACDF

An observational study in Cervical Degenerative Disc Disease, sponsored by Alphatec Spine, Inc.. Terminated at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-03.

Sponsored by Alphatec Spine, Inc. · Observational

How we know

Why this study was terminated
Product is no longer on the market

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 232 studies in Intervertebral Disc Degeneration with a site in United States — 41 open to participants now, 58 under way, 5 of them phase 3. Intervertebral Disc Degeneration · United States.

Enrollment
73rd of 91
30 · median 118
Started
2011
with 7 others
Observational
91 of 232
19 open now
Registered
57th of 232
by date
Lead sponsor
4 of 232
Alphatec Spine, Inc.

Among the 232 studies in Intervertebral Disc Degeneration with a site in United States, this one is the 73rd largest by enrollment of the 91 observational ones that give a count, is one of 8 that started in 2011, is one of 91 observational ones, and was the 57th registered.

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

Browse Intervertebral Disc Degeneration studies →

Open to participants now

41 of the 232 studies in Intervertebral Disc Degeneration with a site in United States are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 232 studies in Intervertebral Disc Degeneration with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the rate and quality of spinal fusion utilizing PureGen Osteoprogenitor Cell Allograft in Anterior Cervical Discectomy and Fusion (ACDF).

Read the detailed description

This is a prospective, multi-center, post-market, observational study assessing subjects undergoing cervical interbody fusion surgery to treat cervical degenerative disc disease (DDD)

Patients diagnosed with cervical degenerative disc disease will be screened for enrollment based on inclusion and exclusion criteria outlined in this protocol. Subjects who are successfully screened and sign an informed consent will undergo ACDF surgery utilizing PureGen, Alphagraft ProFuse Demineralized Bone Scaffold (DBS), a radiolucent cervical interbody spacer, and Trestle or Reveal Anterior Cervical Plating System (plate and screw fixation system).

Subjects will be followed at 6- weeks, 3-, 6-, and 12-month post-operative visits. Standard radiographs will be taken at these visits to assess fusion rate and quality. SF-12, NDI and VAS self assessment questionnaires and neurological exams will be administered to measure pain and function scores. A computerized tomography scan will be taken at the 6 month post operative exam to further assess rate and quality of fusion. A conditional 12-month post operative CT may also be taken. Procedure related and device related adverse events will be monitored throughout the study.

Outcome data will be compared to published and/or retrospective data for the standard of care for DDD patients undergoing ACDF.

03

Conditions studied

  • Cervical Degenerative Disc Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects suffering from symptoms of cervical degenerative disc disease (DDD) in one to four contiguous levels between C3 and T1.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Persistent neck and/or arm pain consistent to symptomatic cervical degenerative disc disease
  • Moderate Neck Disability Index
  • Unresponsive to conservative treatment for at least 6 weeks

Exclusion criteria

Exclusion Criteria:

  • More than 4 levels requiring surgical treatment
  • Prior failed fusion surgery at the index level(s)
  • Systemic or local infection in the disc or cervical spine, past or present
  • Active systemic disease
  • Osteoporosis, osteomalacia, or other metabolic bone disease that would significantly inhibit bone healing
  • Known or suspected history of alcohol and/or drug abuse
  • Involved in pending litigation or worker's compensation relating to the spine
  • Pregnant or plans to become pregnant during the duration of the study
  • Insulin-dependent diabetes mellitus
  • less than study duration
  • Any significant psychological disturbance that in the opinion of the Investigator could impair consent process or ability to complete self-assessment questionnaires
  • greater than 40
  • Undergoing chemotherapy or radiation treatment, or chronic use of oral or injected or prolonged use of non-steroidal anti-inflammatory drugs
  • Known history of or anaphylactic reaction to dimethyl sulfoxide (DMSO).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (actual)

Groups and cohorts

  • Cervical Degenerative Disc Disease

    Subjects suffering from symptoms of cervical degenerative disc disease in one to four contiguous levels between C3 and T1.

    Biological: PureGen Osteoprogenitor Cell Allograft

Interventions

  • BiologicalPureGen Osteoprogenitor Cell Allograft

    PureGen Osteoprogenitor Cell Allograft.

06

What researchers measure

Primary outcomes

  1. Fusion

    Proportion of subjects with fusion at the 12-month visit

    Time frame: 12 months

07

Study locations

4 sites
  • Alphatec Spine Inc.
    Carlsbad, California 92008, United States
  • Middletown, Connecticut 06457, United States
  • Greensboro, North Carolina 27401, United States
  • Raleigh, North Carolina 27607, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Feb 2012 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 4, 2011
First posted
Feb 8, 2011
Start
Feb 2011
Primary completionActual
Feb 2012
CompletionActual
Aug 2013
Last update
Mar 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01291134
Lead sponsor
Alphatec Spine, Inc.
Responsible party
Sponsor
First posted
Feb 8, 2011
Start date
Feb 2011
Primary completion
Feb 2012
Completion
Aug 2013
Last update
Mar 3, 2022

Study contacts

Bita P. Ghadimi
study director · Alphatec Spine, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion